← Patent-cliff monitor small molecule GIVLAARI GIVOSIRAN SODIUM
Loss of exclusivity October 2034 latest FDA-listed patent expiry
Drug detail Brand name GIVLAARI Active ingredient GIVOSIRAN SODIUM Strength EQ 189MG BASE/ML (EQ 189MG BASE/ML) Dosage form SOLUTION Route SUBCUTANEOUS Modality Small molecule FDA approval November 2019 Marketing status RX
Listed patents Patent Expires Type 11028392 October 2034 substance, product 10119143 October 2034 substance, product 9133461 November 2033 substance, product 10125364 March 2033 substance, product 9631193 March 2033 use U-2672 8106022 December 2029 substance, product 8828956 December 2028 substance, product 10131907 August 2028 substance, product
Regulatory exclusivity Code Expires ODE-273 November 2026
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.